# OnCo record pralsetinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pralsetinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pralsetinib" ;
  schema:name "Pralsetinib"@en ;
  schema:description "Pralsetinib is the second selective RET pill for lung cancer, less used than selpercatinib after a change of owner and label."@en ;
  schema:url <https://onco.cc/drugs/pralsetinib/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pralsetinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q97732199> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pralsetinib>, <https://www.nice.org.uk/guidance/ta812> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (RET)" ;
  schema:alternateName "Gavreto" ;
  onco:approval "US 2020: RET-fusion metastatic NSCLC (full approval 2023)", "England (NICE) 2022: RET fusion-positive advanced non-small-cell lung cancer in patients who have not had a RET inhibitor: not recommended" ;
  onco:acceleratedApproval "US 2020-09-04: Treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test", "US 2020-12-01: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy", "US 2020-12-01: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)" ;
  onco:acceleratedApprovalConfirmed "US 2023-08-09: Treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test" ;
  onco:related <https://onco.cc/biomarkers/ret-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/medullary-thyroid-cancer/>, <https://onco.cc/cancers/ret-fusion-nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ret/> ;
  onco:drugs <https://onco.cc/drugs/selpercatinib/> ;
  onco:companies <https://onco.cc/companies/blueprint-medicines/>, <https://onco.cc/companies/rigel-pharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/nct04302025/>, <https://onco.cc/trials/arrow-thyroid/> .